期刊文献+

顺铂联合吉西他滨与紫杉醇治疗晚期非小细胞肺癌的临床疗效比较研究 被引量:3

Clinical effect comparison reaserch of cisplatin combined with gemcitabine and paclitaxel in the treatment of advanced non-small cell lung cancer
下载PDF
导出
摘要 目的比较顺铂联合吉西他滨与紫杉醇治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法选取四川省司法警官总医院2014年5月—2016年5月收治的晚期NSCLC患者168例,随机将患者分为对照组与研究组,各84例。对照组予以顺铂联合紫杉醇治疗,研究组予以顺铂联合吉西他滨治疗,两组患者均持续治疗2个化疗周期。比较两组患者临床疗效、毒副作用发生情况。结果两组患者临床疗效比较,差异无统计学意义(P>0.05)。研究组患者白细胞计数减少程度优于对照组,血小板计数减少程度差于对照组(P<0.05);两组患者血红蛋白下降、恶心呕吐、脱发、肝功能损伤、肾功能损伤发生情况比较,差异无统计学意义(P>0.05)。结论顺铂联合吉西他滨与紫杉醇治疗晚期NSCLC的临床疗效相当。 Objective To compare the clinical effect of cisplatin combined with gemcitabine and paclitaxel in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 168 cases of patients with advanced NSCLC were selected from May 2014 to May 2016 in Police Officers General Hospital of Sichuan Province,which were randomly divided into control group and study group,84 cases in each group.Control group was given cisplatin combined with paclitaxel,study group was given cisplatin combined with gemcitabine,both groups were treated for two cycles of chemotherapy.The clinical effect and the toxic and side effects were compared between the two groups.Results There was no significant difference of clinical effect between the two groups(P〉0.05).The study group of white blood cell count reduction was better than control group,decrease degree of platelet count was worse than control group(P〈0.05).No significant differences of the incidence of hemoglobin decreasing,nausea and vomiting,alopecia,liver function damage or renal damage was found between the two groups(P〉0.05).Conclusion Cisplatin combined with gemcitabine has a same efficacy in the treatment of advanced NSCLC with paclitaxel.
出处 《临床合理用药杂志》 2017年第18期5-6,共2页 Chinese Journal of Clinical Rational Drug Use
关键词 肺肿瘤 顺铂 吉西他滨 紫杉醇 治疗结果 Lung neoplasms Cisplatin Gemcitabine Paclitaxel Treatment outcome
  • 相关文献

参考文献6

二级参考文献47

  • 1邓立春,茅卫东,许晨.GP方案和MVP方案治疗晚期非小细胞肺癌的比较研究[J].临床肿瘤学杂志,2004,9(3):305-306. 被引量:2
  • 2孙燕 周际昌.临床肿瘤内科手册[M].北京:人民卫生出版社,1996.30-33.
  • 3Manegold C,Zatloukal P,Krejcy K,et al.Gemcitabine in non-small-cell lung cancer.Invest New Drugs,2000,18(1):29-42.
  • 4Raez L E,Lilenbaum R.New developments in chem othe rapy for advanced non-small cell lung cancer.Curr Opin Oncol,2006,18(2):156-161.
  • 5Einhorn L H.first-line chem othe rapy fo non-small-cell lung cancer is there a superior regimen based on histology.J Clin Oncol,2008,26(21):3485-3486.
  • 6Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ER- CC1 in non-small-cell lung cancer and cisplatin-bascd adjuvant chemotherapy[J]. N Engl J Med, 2006, 355(10) :983 -991.
  • 7Davidson JD, Ma L, Flagella M, et al. An increase in the ex pression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer eel lines[J]. CancerRes, 2004, 64(11):3761 -3766.
  • 8Marlin I,P, Hamilton TC, Schilder RJ. Plalinum resistance:the role of DNA repair pathways[ J]. Clin Cancer Res, 2008, 14 (5) :1291 - 1295.
  • 9Smon GR, Sharma S, Cantor A, et al. ERCCI expression is a predictor of survival in resected patients with non-small cell lung cancer [J]. Chest ,2005,127 ( 3 ) :978 - 983.
  • 10Seetharam RN, Sood A, Basu-mallick A, et al. Oxaliplatin re- sistance induced by ERCC1 up-regulation is abrogated by siRNA- mediated gene silencing in human colorectal cancer cells [ J ]. Anticancer Res, 2010, 30(7) :2531 -2538.

共引文献21

同被引文献23

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部